TSE:4568Pharmaceuticals
How Investors Are Reacting To Daiichi Sankyo Company (TSE:4568) Expanding ENHERTU Into First-Line Breast Cancer
In recent weeks, Daiichi Sankyo and AstraZeneca secured a major US FDA approval for ENHERTU plus pertuzumab as first-line treatment for unresectable or metastatic HER2-positive breast cancer, while the EMA validated Daiichi Sankyo’s DATROWAY application for first-line use in certain triple negative breast cancer patients based on positive phase 3 data.
Together with a new AI-enabled biomarker collaboration and ongoing expansion of ENHERTU into ovarian cancer trials, these moves deepen...